A phase I study of the addition of high-dose lenalidomide to melphalan conditioning for autologous stem-cell transplant in relapsed or refractory multiple myeloma

Authors

Usama Gergis MD, MBA, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

9-2015

Volume

15

Issue

3

First Page

291

Last Page

292

Published In/Presented At

10.1016/j.clml.2015.07.596

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine

Document Type

Article